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Abstract 
The aim of this retrospective study was to identify and evaluate complications after hip 
spacer implantation other than reinfection and/or infection persistence. 
Between 1999 and 2008, 88 hip spacer implantations in 82 patients have been performed. 
There were 43 male and 39 female patients at a mean age of 70 [43 – 89] years. The mean 
spacer implantation time was 90 [14-1460] days. The mean follow-up was 54 [7-96] months. 
The most common identified organisms were S. aureus and S. epidermidis. In most cases, the 
spacers were impregnated with 1 g gentamicin and 4 g vancomycin / 80 g bone cement.   
The overall complication rate was 58.5 % (48/82 cases). A spacer dislocation occurred in 15 
cases (17 %). Spacer fractures could be noticed in 9 cases (10.2 %). Femoral fractures oc-
curred in 12 cases (13.6 %). After prosthesis reimplantation, 16 patients suffered from a 
prosthesis dislocation (23 %). 2 patients (2.4 %) showed allergic reactions against the intra-
venous antibiotic therapy. An acute renal failure occurred in 5 cases (6 %). No cases of he-
patic failure or ototoxicity could be observed in our collective. General complications (con-
sisting mostly of draining sinus, pneumonia, cardiopulmonary decompensation, lower urinary 
tract infections) occurred in 38 patients (46.3 %). 
Despite the retrospective study design and the limited possibility of interpreting these find-
ings and their causes, this rate indicates that patients suffering from late hip joint infections 
and being treated with a two-stage protocol are prone to having complications. Orthopaedic 
surgeons should be aware of these complications and their treatment options and focus on 
the early diagnosis for prevention of further complications. Between stages, an interdisci-
plinary cooperation with other facilities (internal medicine, microbiologists) should be aimed 
for patients with several comorbidities for optimizing their general medical condition. 
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Introduction 
Antibiotic-loaded cement spacers have become a 
popular procedure in the treatment of hip joint infec-
tions over the past two decades. Depending on the 
definition of infection eradication and reinfection, hip 
spacers have reportedly a success rate of > 90 % [1].  
Although hip spacers are established as an ade-
quate treatment option in the management of these 
infections, several complications might occur between 
stages and, hence, endanger the functional outcome. 
Besides a reinfection and/or infection persistence, 
mechanical complications, such as spacer fracture, 
spacer dislocation, and femoral fracture, or systemic 
side effects (renal or hepatic failure, allergic reactions) 
might lead to prolonged treatment courses between Int. J. Med. Sci. 2009, 6 
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stages. These complications are certainly rare and the 
exact incidence of the above mentioned complica-
tions, respectively, is still unknown. Moreover, it is 
unclear whether a higher incidence of complications 
between stages might be associated with a higher in-
cidence of mechanical complications after the pros-
thesis reimplantation at the site of a hip spacer im-
plantation. 
Hence, the aim of the present retrospective study 
was to register and define complications after hip 
spacer implantation and prosthesis reimplantation, 
respectively, in the treatment of late hip joint infec-
tions. Specific attention was paid to the aforemen-
tioned mechanical complications, systemic side effects 
as well as general complications. 
Patient – Methods 
All patients’ records that have been treated by 
hip spacer implantation in our institution between 
01.01.1999 and 30.06.2008 have been retrospectively 
evaluated regarding following parameters: primary 
surgical indication, causative pathogen organism, 
time between infection manifestation and spacer im-
plantation, duration of spacer implantation, spacer 
articulation, impregnation of bone cement, systemic 
antibiotics, and implant type at reimplantation. 
Moreover, mechanical complications (spacer disloca-
tion, spacer fracture, femoral fracture, prosthesis dis-
location after reimplantation) and systemic side ef-
fects (renal and hepatic failure, respectively, allergic 
reactions, ototoxicity) as well as general postoperative 
complications were also documented. Only patients 
with a sufficient documentation regarding all above 
mentioned parameters were included in the study. 
From the initially 101 identified patients, 19 pa-
tients were excluded due to insufficient documenta-
tion. From the remaining 82 patients, there were 43 
male and 39 female patients at a mean age of 70 [43 – 
89] years. According to the McPherson classification 
[20], 15 patients were categorized as IIIA1, 4 as IIIA2, 
1 as IIIA3, 25 as IIIB1, 9 as IIIB2, 17 as IIIC1, 10 as 
IIIC2, and 1 as IIIC3. 
The most common primary surgery was a pri-
mary total hip arthroplasty followed by bacterial 
coxitis. Data about primary surgical procedures is 
summarized in Table 1. 
There were 60 mono-, 12 bi-, and 3 polymicrobial 
infections. In 7 cases no causative pathogen organism 
could be identified, however, the histopathological 
findings revealed in all cases signs of osteomyelitis, 
respectively. The most common identified organism 
was Staphylococcus aureus followed by Staphylo-
coccus epidermidis (Table 2).  
Table 1: Primary surgical indications and antibiotic im-
pregnation of the bone cement at the site of spacer im-
plantation in the treatment of hip joint infections. 
Primary surgery   n= Antibiotic impregnation of hip 
spacer (/80 g bone cement) 
 n=
primary THA             45  1 g Gentamicin + 4 g Vancomy-
cin            
77 
bacterial coxitis           15  1 g Gentamicin + 0.8 g Tei-
coplanin             
8 
aseptic cup loosening       8  1 g Gentamicin + 4 g Cefotaxim   2 
osteosynthesis for femo-
ral neck fracture           
5  1 g Gentamicin + 2 g Clinda-
mycin              
1 
aseptic stem loosening       3       
dual head prosthesis         3       
osteosynthesis for inter-
trochanteric fracture       
1       
septic femoral head ne-
crosis                     
1       
resection of heterotopic 
ossifications               
1       
THA: total hip arthroplasty 
Table 2: Pathogen organisms in late hip joint infections. 
Organism n= 
S. aureus  25 
S. epidermidis  25 
E. faecalis  8 
MRSA 8 
E. coli  6 
ß-hem. Streptococci  5 
Ps. aeruginosa  3 
C. albicans  3 
a-hem. Streptococci  2 
K. pneumoniae  2 
S. capitis  1 
S. haemolyticus  1 
S. hominis  1 
S. agalactiae  1 
E. faecium  1 
P. mirabilis  1 
Str. auginosus  1 
Bacillus sp.  1 
Streptococci sp.  1 
Peptostreptococci sp.  1 
gram+ cocci  1 
( no further specification)    
MRSA: methicillin-resistant S. aureus 
 
Antibiotics were administered in all cases after 
consultation with our Microbiologic Institute. The 
most common combination used was vancomycin 
and rifampicin followed by clindamycin and fluclox-
acillin (data not shown in a table). If no bacterium 
could be isolated, a broad spectrum antibiosis (flu-
cloxacillin and clindamycin) was prescribed. If the 
general medical condition allowed for it and no anti-
biotic-related complications occured, antibiotics were 
given intravenous for the first 4 weeks followed by 
oral antibiotics for another two weeks. 
In these 82 patients, 88 spacer implantations 
have been performed (in 5 patients spacer exchange, Int. J. Med. Sci. 2009, 6 
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in one case bilaterally). The time between infection 
manifestation and spacer implantation was meanly 6 
[1-108] weeks. All infections were late infections ex-
cept for the cases suffering from a bacterial coxitis. 
The mean spacer implantation time was 90 [14-1460] 
days. The mean follow-up of these 82 patients was 54 
[7-96] months. 
All patients have been treated by the same 
one-size custom-made spacer. The spacer has been 
intraoperatively produced by means of a two-parted 
mould. The mould consists of polyoxymethylene 
(POM). In all cases Refobacin – Palacos (0.5 g gen-
tamicin/ 40 g cement) has been used due to its supe-
rior elution characteristics compared with other bone 
cements [1]. For the spacer production 80 g of poly-
methylmethacrylate (PMMA) are required. Depend-
ing on the causative pathogen organism and its sensi-
tivity profile the bone cement was optionally loaded 
with a second antibiotic. In cases of a preoperative 
unidentified bacterium or if the infection was re-
vealed during the operation for presumed aseptic 
conditions, the combination of 1 g gentamicin/ 4 g 
vancomycin/ 80 g PMMA was routinely used. Each 
spacer has a head diameter of 50 mm, a stem length of 
10 cm, and a total surface area of 13300 mm² [3].   
In case of acetabular defects a special mould is 
also available. The acetabular component has an in-
side/outside diameter of 53/ 56 mm and a total sur-
face area of 4410 mm² [3].  
From the 88 spacers implanted, 82 acted as a 
hemiarthroplasty, whereas only in 6 cases a spacer 
cup has been implanted. In 70 cases a “normal” spacer 
has been implanted, whereas in the remaining 18 
cases a spacer head has been placed onto the in situ 
remained femoral stem. In the latter cases, there was 
either an isolated septic cup loosening at no stem in-
fection as primary indication, or due to the type of 
implant primarily used or due to the femoral bone 
quality (associated with a higher risk of femoral frac-
ture) we decided not to remove the femoral stem. 
For loading of the bone cement, the combination 
of gentamicin and vancomycin was most frequently 
used followed by the combination of gentamicin and 
teicoplanin. Data about the antibiotic impregnation of 
hip spacers is summarized in Table 1. 
After six weeks of antibiotic treatment, the anti-
biotics were paused and the serum C-reactive protein 
(CRP) checked. If its level had returned to normal, 
two weeks later another CRP-control was performed. 
If also normal, the second stage was planned if the 
wound had healed and the general medical condition 
of the patient allowed for it. 
A total prosthesis reimplantation was performed 
in 63 cases. In 24 cases cementless components have 
been reimplanted, in 20 cases hybrid, in 10 cemented, 
and in 9 patients reverse hybrid. In one case, the pros-
thesis reimplantation was performed elsewhere. In 12 
cases, only a cup reimplantation was performed 
(“spacer head” group). 5 patients passed away be-
tween stages, whereas in 7 cases the spacer remained 
in situ because either the patient was not willing to 
undergo further surgery or because the comorbidities 
of the patient did not allow the prosthesis reimplan-
tation.  
Results 
Mechanical complications 
A spacer dislocation occurred in 15 cases (17 %). 
From these 15 cases, 12 patients have been treated 
conservatively by reduction and immobilization in a 
hip orthesis (Newport orthesis, Fa. Ormed, Freiburg, 
Germany) during the remaining time between stages. 
The other three cases underwent further surgical 
procedures; in one case (combined spacer dislocation 
and -fracture), the spacer had been exchanged, 
whereas the other two cases had been treated by re-
section arthroplasty after recurrent spacer disloca-
tions and unsuccessful conservative treatment.     
Spacer fractures could be noticed in 9 cases (10.2 
%). 7 of them were localized in the distal part of the 
spacer stem and were asymptomatic. The other two 
cases were spacer-neck fractures and had been treated 
by subsequent spacer exchange. 
In one case a spacer protrusion was evident over 
time and the patient was advised to put no weight 
bearing on the leg. 
Femoral fractures occurred in 12 cases (13.6 %). 5 
out of these 12 cases occurred at the first stage and 
were treated by implantation of an antibiotic-coated 
femoral nail and spacer implantation on top. Four 
cases with a femoral scissure, respectively, were man-
aged by minimal weight-bearing of the particular ex-
tremity. One case suffering from an avulsion of the 
minor trochanter was treated by cerclage refixation. 
After prosthesis reimplantation, one patient suffered 
from a periprosthetic fracture which was treated with 
a plate osteosynthesis. One patient had a fracture be-
neath the spacer stem and was treated by implanta-
tion of an antibiotic-coated prosthesis stem and 
placement of a spacer head onto the stem. 
After prosthesis reimplantation, 16 patients suf-
fered from a prosthesis dislocation (23 %). 12 cases 
could be successfully managed by reduction and 
immobilization in a hip orthesis for the following 12 
weeks. The other 4 cases had recurrent dislocations 
and were managed by acetabular socket explantation 
and implantation of a constrained cup (Fa. Waldemar Int. J. Med. Sci. 2009, 6 
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Link, Hamburg, Germany), respectively. 
Systemic side effects 
2 patients (2.4 %) showed allergic reactions (rash 
and pruritus) against the intravenous antibiotics ad-
ministered (in both cases combination of clindamycin 
and flucloxacillin). The symptoms were resolved after 
adjustment of the antibiotic therapy. 
An acute renal failure occurred in 5 cases (6 %). 2 
patients could be successfully treated conservatively, 
whereas 2 patients had to be treated by renal dialysis. 
One patient suffering from multiple myeloma passed 
away after renal failure and cardiopulmonary de-
compensation. Unfortunately, the retrospective 
evaluation of the patients’ records did not allow any 
differentiation of the particular cause of the renal 
failure, respectively (antibiotic-impregnation of the 
spacer, systemic antibiotics, other medication). 
No cases of hepatic failure or ototoxicity could be 
observed in our collective. 
General complications 
General complications (other than the aforemen-
tioned ones) occurred in 38 patients (46.3 %). 
4 patients had a draining sinus after the first 
stage and 6 after the second stage, respectively. Of 
these 10 cases, 2 resolved after local treatment, 
whereas the other 8 have been treated by revision, 
haematoma removal and pulsatile lavage. None of 
these patients had a reinfection or infection persis-
tence during follow-up. 
6 patients suffered from a pneumonia which 
could be treated successfully with antibiotics in all 
cases. 
In 5 cases after spacer implantation and in 2 
cases after prosthesis reimplantation a cardiopul-
monary decompensation emerged which could be 
successfully managed by adjustment of the cardiac 
medication and fluid restriction, respectively. 
One patient denied a prosthesis reimplantation. 
In this case, the patient started to increase 
weight-bearing on the leg 3 months after spacer im-
plantation. 13 months later, X-rays revealed an as-
ymptomatic acetabular fracture without any spacer 
dislocation. At a follow-up of 52 months the patient is 
still free of any infection signs and has no complaints 
at an almost free range of motion.  
4 patients developed postoperatively a transitory 
psychotic syndrome which regressed over the first 2 
weeks, respectively.  
3 patients had an antibiotic-associated colitis by 
Clostridum difficile and have been orally treated with 
vancomycin. Also 3 patients had a central venous 
catheter – associated sepsis. A thrombosis, epileptic 
seizures, and lower urinary tract infections could be 
noticed in 2 cases, respectively. A pleura empyema, a 
heparin-induced thrombocytopenia (HIT), a case of 
pelviperitonitis with bladder necrosis and subsequent 
surgical intervention, a cholecystitis with subsequent 
cholecystectomy, a myocardial infarction, and an in-
farction of the A. cerebri media could be observed in 
one case, respectively. 
2 patients passed away after the first stage and 2 
after the second stage due to cardiopulmonary de-
compensation, respectively. As already mentioned, 
one patient suffering from multiple myeloma passed 
away after renal failure and cardiopulmonary de-
compensation.  
The overall complication rate was 58.5 % (48/82 
cases). 
Discussion 
A reinfection and/or infection persistence are 
the most feared complications after hip spacer im-
plantation because they can be both associated with 
subsequent surgical revisions and higher morbidity 
and mortality rates, respectively. However, several 
other complications might also occur during a 
two-stage treatment protocol for late hip joint infec-
tions which can also lead to prolonged treatment 
courses and endanger the functional outcome. Al-
though these complications are frequently not men-
tioned or insufficiently documented in the literature, 
they are surely of no minor value compared with an 
infection persistence or reinfections.  
Mechanical complications 
Mechanical complications belong certainly to the 
most important complications after hip spacer im-
plantation because they are often associated with 
subsequent surgical interventions and may impair the 
functional outcome. 
The exact incidence of mechanical complications 
is unknown. Hereby, several parameters might play a 
role: the spacer’s production (hand-made vs. stan-
dardized), the spacer’s geometry, the head/neck ratio, 
acetabular and/or femoral defects, mismatch of 
spacer’s head size to the acetabulum size, the art of 
femoral fixation, muscular insufficiency, prior surgi-
cal revisions, poor bone quality, and incompliance of 
the patient with regard to partial weight bearing.  
A review of the literature about hip spacers 
showed a tendency that hand-made spacers might 
dislocate more often than standardized-made ones 
[1]. However, a significant difference could not be 
assessed due to inhomogenities of the patients’ col-
lectives and insufficient documentation regarding the 
spacer production and fixation, respectively. 
Leunig et al. [18] were one of the first who tried Int. J. Med. Sci. 2009, 6 
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to interpret and explain these findings. The authors 
have recognized that the geometrical form of the 
spacer plays an important role. In spacers which were 
free of complications, the neck to head-ratio was sig-
nificantly lower (0.76±0.05) than in those with dislo-
cations (0.96±0.19). A second factor associated with 
failure was an insufficient deep anchorage in the in-
tramedullary canal, being 22±33 mm in the failure 
group, while complication-free spacers were on av-
erage attached to a depth of 57±41 mm. 
Regarding the femoral fixation of hip spacers, 
there exist to our knowledge 3 methods: i) press-fit, ii) 
partially or totally cementation, and iii) the “glove“ – 
technique [3]. The latter technique has been recently 
described and provides a stable fixation onto the 
proximal femur at facilitating the spacer’s explanta-
tion since the spacer can be removed at one piece and 
there is no need for removal of any cement debris 
compared with other normal cementation techniques. 
However, it is unclear, which of the above mentioned 
techniques is the most superior one in the prevention 
of spacers’ dislocations regarding the femoral part. 
In the literature, the dislocation rates after hip 
spacer implantation may strongly vary depending on 
the art of the spacer’s production as well as the fixa-
tion method. Leunig et al. [18] reported dislocations of 
the hip in 5 of 12 patients after use of hand-formed 
spacers, whereas Magnan et al. [19] and Duncan et al. 
[9] could notice a rate of 1/10 and 3/13 dislocations 
after implantation of a standardized hip spacer, re-
spectively. On the other hand, Ries and Jergesen [26], 
Koo et al. [16], Shin et al. [30] and Takahira et al. [33] 
could not observe any dislocation during implanta-
tion of standardized spacers, respectively. 
In our collective we could notice a spacer dislo-
cation rate of 17 %. This rate might appear high, 
however, this is the rate of a 10-year collective. Over 
the years we have gained experience with this treat-
ment option, and advances in the surgical technique, 
instruments and fixation method have led to a re-
duced rate over the last years. We have also made the 
experience that careful education of the patients by 
our physiotherapists with regard to walking attitude, 
partial weight bearing and joint motion is very im-
portant in the prevention of dislocations. Certainly, a 
disadvantage of our treatment protocol is the one-size 
spacer which has been implanted in all cases. Perhaps, 
if we have had several moulds for spacer production 
and each case would have been treated by a more 
“anatomical” spacer, the dislocation rate might have 
been lower. 
The rate of spacer fractures in our series was 
approximately 10 %. Interestingly, the majority of the 
cases had no symptoms at all and only in 2 cases the 
spacer had to be exchanged in an additional surgery. 
For prevention of a spacer fracture, the surgeon may 
consider inserting a metallic endoskeleton into the 
spacer; however, literature data are scarce about this 
topic. Schöllner et al. investigated in vitro the me-
chanical properties of gentamicin-loaded hip spacers 
after insertion of Kirschner wires [31]. Stress experi-
ments showed an average failure load of 1.6 kN. The 
insertion of the K-wires prevented any dislocation of 
the spacer fragments, but did not significantly im-
prove the mechanical properties. Kummer et al. 
compared in vitro the mechanical properties of com-
mercially available hip spacers containing a substan-
tial stainless steel central core with experimental 
spacers containing Steinmann pins, intramedullary 
nails with two lag screws and Charnley prostheses, 
respectively [17]. The authors reported that all con-
structs based upon the Charnley prostheses and the 
commercial spacers did not fail at 3000 N; the other 
two constructs failed at significant lower loads (pins 
at 832 N and nails at 1275 N, respectively). Thielen et 
al. investigated in vitro the mechanical stability of 
reinforced hip spacers (either a rod pin with a 5 mm 
diameter or a “full-stem” endoskeleton; both consist-
ing of titanium grade two) compared with 
non-reinforced spacers [34]. At cycling testing, non-
reinforced spacers failed at 400-600 N, whereas 
rod-reinforced spacers failed at 1000-1300 N. 
“Full-stem” reinforced spacers failed at 2380-4311 N, 
depending on the thickness of endoskeleton used 
(6/8/10 mm). To our knowledge, there are no clinical 
data available that have demonstrated that the inser-
tion of a metallic endoskeleton significantly improves 
the mechanical properties of hip spacers or reduces 
the rate of mechanical complications. 
Moreover, it is still unclear whether the insertion 
of a metallic endoskeleton has a negative influence on 
the pharmacokinetic properties of the spacer. Ex-
perimental data have shown that the release of com-
mercially-impregnated antibiotics from hip spacers is 
significantly increased in the presence of an endo-
skeleton, whereas the elution of additional, incorpo-
rated antibiotics is decreased [2]. Until this question is 
answered, we recommend that metallic endoskeletons 
should not be routinely inserted into hip spacers in 
clinical practise, but only in exceptional cases for pa-
tients with a higher fracture risk (poor patient com-
pliance, high Body-Mass-Index, poor bone quality or 
osteoporosis). 
Femoral fractures occurred in 12 cases (13.6 %) in 
our series. Hereby, a differentiation should be made 
between those at the first stage, between stages, and 
after prosthesis reimplantation, respectively. More-
over, not every fracture has to be surgically treated, as Int. J. Med. Sci. 2009, 6 
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seen in our collective. Some predisposing factors 
which might lead to a femoral fracture include os-
teoporosis, poor bone quality due to prior surgeries or 
bone defects resulting after the prosthesis explanta-
tion. In these cases the orthopaedic surgeon should 
plan the first and second stage taking into considera-
tion the possibility of a bone fracture and reconstruc-
tive strategies regarding both infection eradication 
and fracture treatment. 
The etiology of dislocations after total hip ar-
throplasty is often multifactorial. In their review 
work, Pulido et al. identified female gender, older 
patients, neurological dysfunction or cognitive im-
pairment, and a preoperative diagnosis of osteone-
crosis of the femoral head, femoral neck fracture 
and/or inflammatory arthritis as patient risk factors 
for early dislocation after primary THA [24]. The 
presumed etiological factors for late instability in-
clude long standing malpositioning of the compo-
nents, trauma, deterioration in muscle, mass, neuro-
logical status impairment and polyethylene wear [24]. 
The postoperative dislocation rate following 
reimplantation after two-stage treatment protocols 
has been reported to range from 6 to 18 % [6, 12]. In 
their study, Hsieh et al. reported a dislocation rate of 
14.3 % in patients treated by resection arthroplasty 
compared to 1.8 % in patients treated by insertion of 
an antibiotic-loaded hip spacer at a mean follow-up of 
4.9 years [6]. Hartmann and Garvin reported a 14.7 % 
dislocation rate in patients having prosthesis reim-
plantation after infection compared with 1.7 % in pa-
tients having revision for aseptic failure [11]. Fehring 
et al observed a 25% dislocation rate in 56 hips despite 
adequate soft tissue tension and appropriately placed 
prosthetic components [10]. The authors tried to in-
terpret these findings, but found no statistical differ-
ences between dislocators and nondislocators re-
garding head size, acetabular component size, neck 
length, liner design, time between stages, abduction 
angle of the acetabular component and leg length dis-
crepancy, respectively. Fehring and colleagues sup-
posed that this high rate might have been related to 
the use of nonarticulating spacers and the use of ar-
ticulating spacers might have had an effect on these 
results. 
Despite the assumption of Fehring and col-
leagues, we could observe in our collective a prosthe-
sis dislocation in 23 % of the cases. We believe that 
this high dislocation rate after prosthesis reimplanta-
tion can be explained by following thesis: every sur-
gical procedure causes trauma to the local tissues, 
leading to muscle and bone loss. Proper debridement 
of the infected hip requires often debridement of 
bone. Bone loss makes proper component position 
difficult, leading to potential malposition and in-
creasing the risk of instability. Multiple surgical revi-
sions also increase the risk of developing abductor 
dysfunction. As the abductors become less functional, 
their important role in hip stability is lost. We believe 
this is a very important topic, and patients undergo-
ing a two-stage protocol in the treatment of hip joint 
infection should be preoperatively informed about it, 
especially those having already undergone surgical 
revisions for infection management. Perhaps, it would 
be advisable to use constrained acetabular compo-
nents in these cases. 
Hip joint instability after two-stage treatment is 
still a major problem. Fehring et al. estimated that 
approximately 400 patients would be needed for the 
standard power value of 80% for the aforementioned 
statistical differences [10]. Such a number is difficult 
to achieve in a single-center study, however, in a 
multicenter study other factors, such as sur-
geon-related parameters (experience, surgical tech-
nique, instruments) may influence the outcome.    
Systemic side effects 
Antibiotic-loaded beads and spacers can locally 
release high antibiotic concentrations which vastly 
exceed those after systemic administration with no or 
low systemic toxicity. Salvati et al. have investigated 
urine and serum samples after implantation of gen-
tamicin-loaded cement and beads in 38 and 18 pa-
tients, respectively, and could observe no toxic effects 
in these patients at very low gentamicin levels [28]. 
Springer et al. could also not observe any toxic effects 
even after a very high impregnation of knee spacers 
with antibiotics (average 3 g vancomycin + 3.6 g gen-
tamicin / 40 g PMMA) in 34 patients and concluded 
that drug delivery device with a high antibi-
otic/cement-ratio should be regarded safe for clinical 
use [32].   
Despite these reports, an increasing number of 
cases have been published regarding systemic side 
effects after use of bone cement drug delivery systems 
in the past years. Van Raaij et al. reported the case of 
an 83 year old woman with no history of kidney dis-
ease who developed acute renal failure (ARF) after 
resection of an infected total knee arthroplasty and 
placement of a gentamicin-impregnated cement 
spacer (2 g gentamicin / 40 g PMMA) and 7 chains of 
30 gentamicin beads (0.945 g gentamicin) [35]. Serum 
gentamicin levels indicated high concentrations that 
prompted removal of the spacer and subsequent re-
turn of normal renal function. Patrick et al. reported 
two similar cases of ARF in an 82 year old female and 
a 79 year old male patient, 5 months and 6 weeks after 
implantation of a vancomycin-tobramycin-loaded hip Int. J. Med. Sci. 2009, 6 
 
http://www.medsci.org 
271
spacer, respectively [23]. In both cases the serum to-
bramycin concentration was elevated, but after spacer 
explantation serum creatinine and antibiotic concen-
trations returned to within normal limits, respec-
tively. Similar cases have also been described by Cur-
tis et al. [7] and Dovas et al. [8] after use of tobramy-
cin- and gentamicin-vancomycin-impregnated spac-
ers at the site of infected total knee arthroplasties, 
respectively.  
Koo et al. reported 2 cases of hepatic failure and 
2 cases of bone marrow depression, respectively, after 
hip spacer implantation (1 g gentamicin + 1 g van-
comycin + 1 g cefotaxime / 40 g PMMA) out of 22 
cases [16]. The authors stated that the side effects were 
resolved after temporary withdrawal of the systemic 
antibiotics, however, it is unknown which systemic 
antibiotics have been used in each case. Isiklar et al. 
found one case of ARF out of 10 patients after im-
plantation of a vancomycin-loaded hip spacer (2-3 g 
vancomycin / 40 g PMMA) and intravenous admini-
stration of the same antibiotic [14]. Cabrita et al. ob-
served 1 case of renal failure and 3 cases of allergic 
reactions out of 33 cases of hip spacer implantation (1 
g tobramycin + 1 g vancomycin / 40 g PMMA) [5]. 
Unfortunately, no further details are available about 
the systemic antibiotics used in the particular cases 
nor the causes of the renal failure or of the allergic 
reactions, respectively.  
In the latest evaluation of the PROSTALAC ex-
perience, Wentworth et al. reported one case of an 
allergic (dermatologic) reaction to vancomycin out of 
135 cases of hip spacer implantation, whereas no pa-
tients had suffered from any renal or hepatic failure 
[36]. Also using the PROSTALAC system, Scharfen-
berger et al. reported one case of neutropenia after 
intravenous administration of vancomycin after hip 
spacer implantation in 28 patients, while no cases of 
renal of hepatic insufficiency could be observed [29]. 
Despite the abovementioned reports, several 
points remain unclear regarding to these phenomena. 
Sometimes, these observations are only mentioned in 
the particular articles, however, no further details 
about the exact cause are given so that only specula-
tions can be made. In some cases, renal failure might 
be attributed to the local and systemic combination of 
the same or different antibiotic groups with nephro-
toxic potential. Interestingly, it seems that the local 
combination of two potentially nephrotoxic antibiotic 
groups (aminoglycosides and glycopeptides) alone 
does not always induce any systemic side effects, but 
when combined with an intravenous antibiotic which 
also has a nephrotoxic potential, this acts as a trigger 
and that effect might occur. Whether these patients 
have a genetic predisposition towards such an antibi-
otic treatment and the occurrence of such complica-
tions is unknown. Moreover, it is unclear if the age of 
the patient plays a role in the emergence of ARF. In 
most cases elderly patients have suffered from such 
systemic side effects. Furthermore, no certain expla-
nation exists why in some cases the aminoglycoside 
and in others the glycopeptide generates the nephro-
toxic effect. The time of ARF manifestation might also 
vary strongly among the reported cases without hav-
ing any precise explanation for this discrepancy.  
Until the exact etiology of renal or hepatic failure 
is cleared, perhaps it would be advisable to avoid 
such combinations (highly antibiotic-loaded cement 
and systemic antibiotics of the same group) in risk 
(elderly) patients as long as this is in accordance with 
the antibiogram of the causative bacterium and does 
not endanger the infection sanitation. Careful and 
frequent monitoring of the laboratory parameters are 
indicated in the detection of antibiotic-induced bone 
marrow depression and assist to an early adjustment 
of the antibiotic therapy. 
Our data confirm the rare emergence of these 
systemic side effects. An acute renal failure occurred 
in 6 % of the cases, whereas allergic reactions were 
seen in only 2 % of the cases. Our rates are in accor-
dance with those of the literature, however, physi-
cians should be also aware of these infrequent com-
plications, since they might even result to death. 
General complications 
Patients suffering from late hip joint infections 
have usually several comorbidities. General compli-
cations, especially other infections (pneumonia, lower 
urinary tract infections) or cardiopulmonary decom-
pensation, might lead to a further deterioration of the 
immunosuppressive status of the patient and either 
have a negative influence on the joint infection eradi-
cation process or extend the time between stages or 
both.  
Patel et al. investigated factors associated with 
prolonged wound drainage after primary total hip 
arthroplasty [22]. The authors found that increased 
drain output, prophylaxis with low-molecular-weight 
heparin, and morbid obesity (body mass index > 40) 
were independent risk factors for prolonged wound 
drainage, and this in return was a significant predictor 
of wound infection. Each day of prolonged drainage 
was associated with a 42% increase in the risk of 
wound infection. Similar findings have been also re-
ported by Saleh et al. and Knobben et al. [15, 27]. In 
our collective, we have had 10 cases with a draining 
sinus, of which 8 had surgical treatment. None of 
these patients had a reinfection or infection persis-
tence. Hereby, we believe that the early surgical revi-Int. J. Med. Sci. 2009, 6 
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sion of the haematoma is an indispensable premise in 
the prevention of a wound infection.  
Besides draining sinus, other infections during 
the two-stage protocol might endanger the treatment 
course. Irvine et al. found in a study of 274 patients 
who underwent total hip replacement that of the 5 
patients with deep joint sepsis who had preoperative 
urinary tract infections, 3 had evidence of the same 
organism of both the urinary tract and the hip pros-
thesis [13]. Pulido et al. tried recently to identify pre-
disposing factors for periprosthetic joint infections at 
the site of primary hip or knee arthroplasty [25]. Uri-
nary tract infection was one of nine factors identified 
after multivariable logistic regression analysis. The 
authors proposed that if urinary infection is preop-
eratively confirmed, the patients should receive ap-
propriate antibiotic therapy for infection eradication 
before proceeding with joint arthroplasty. Moreover, 
among the predisposing factors identified in this 
study was the development of postoperative atrial 
fibrillation and myocardial infarction. The authors 
suggested that a possible explanation might be that all 
patients with serious cardiac complications receive 
aggressive anticoagulation with heparin or similar 
agents, and use of aggressive anticoagulation has 
been reported as an independent risk factor for pe-
riprosthetic joint infections [21]. Another explanation 
might be that these complications occur in patients 
who generally are sicker and older with pre-existent 
medical conditions that would retard wound healing 
resulting in later infection. 
The emergence of a pneumonia in patients suf-
fering from late hip joint infections might also prolong 
the hospitalization stay and, hence, complicate the 
postoperative treatment course. Although organisms 
causing pneumonia are infrequently identified in joint 
infections, there exist reports about such cases at the 
site of hip surgery [4, 37]. 
Apparently, patients with late hip joint infections 
are a multimorbid collective. Since general complica-
tions occur at a high rate, as our study demonstrates, 
an interdisciplinary cooperation with other facilities, 
especially with the departments of internal medicine, 
microbiology and haemostasiology, is advisable for 
adequate treatment of these complications and reduc-
tion of morbidity and mortality rates, respectively.  
Conclusion 
Antibiotic-loaded cement spacers are an efficient 
method in the treatment of hip joint infections. How-
ever, during treatment several complications might 
occur that might endanger the infection eradication as 
well as the functional outcome after prosthesis reim-
plantation. Our data demonstrate that > 50 % of pa-
tients suffering from hip joint infections and treated 
with a two-stage protocol will have some kind of 
complications besides reinfection or infection persis-
tence, mostly consisting of mechanical ones (spacer 
fracture, -dislocation, femoral fracture, prosthesis 
dislocations), systemic side effects (acute renal failure, 
allergic reactions), and general complications (drain-
ing sinus, pneumonia, etc.). Despite the retrospective 
design of our study and the limited possibility of in-
terpreting these findings and their causes, this rate 
indicates that these patients are prone to have some 
kind of complication. Orthopedic surgeons should be 
aware of these complications and their treatment op-
tions and concentrate on the early diagnosis for pre-
vention of further complications. Between stages, an 
interdisciplinary cooperation with other facilities (in-
ternal medicine, microbiologists) should be aimed for 
patients with several comorbidities for optimizing 
their general medical condition.  
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